Genentech Releases SMA Community Letter with Evrysdi (risdiplam) Updates

December 7, 2023 / No Comments / ,
Genentech, a member of the Roche Group, logo

Our partners at Genentech recently provided an SMA Community Letter regarding Evrysdi® (risdiplam) and their clinical development program.

Visit this link to learn more.

Do you like what you're reading?

Help make a difference in the lives of people affected by spinal muscular atrophy.

Posted in ,

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top
<!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: SMAAM Lightbox #2 --> <script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,291506,'nlbergwrhtqnmjvuvg7q');</script> <!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Basic Research Grants --> <script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,291506,'idozqmam4bpvlvdmsvzd');</script> <!-- / OptinMonster -->